Randomized, open-label, perioperative phase II study evaluating nivolumab alone versus nivolumab plus ipilimumab in patients with resectable HCC

A. Kaseb; L. Vence; J. Blando; S. Yadav; N. Ikoma; R. Pestana; J. Vauthey; H. Cao; Y. Chun; D. Sakamura; R. Wolff; J. Yao; J. Allison; P. Sharma

doi:10.1093/annonc/mdz156.008

Randomized, open-label, perioperative phase II study evaluating nivolumab alone versus nivolumab plus ipilimumab in patients with resectable HCC

A. Kaseb, L. Vence, J. Blando, S. Yadav, N. Ikoma, R. Pestana, J. Vauthey, H. Cao, Y. Chun, D. Sakamura, R. Wolff, J. Yao, J. Allison, P. Sharma

Research output: Contribution to journal › Article › peer-review

Original language	English (US)
Pages (from-to)	iv112
Journal	Annals of Oncology
Volume	30
DOIs	https://doi.org/10.1093/annonc/mdz156.008
State	Published - Jul 2019

ASJC Scopus subject areas

Hematology
Oncology

Access to Document

10.1093/annonc/mdz156.008

Cite this

Kaseb, A., Vence, L., Blando, J., Yadav, S., Ikoma, N., Pestana, R., Vauthey, J., Cao, H., Chun, Y., Sakamura, D., Wolff, R., Yao, J., Allison, J., & Sharma, P. (2019). Randomized, open-label, perioperative phase II study evaluating nivolumab alone versus nivolumab plus ipilimumab in patients with resectable HCC. Annals of Oncology, 30, iv112. https://doi.org/10.1093/annonc/mdz156.008

Kaseb, A, Vence, L, Blando, J, Yadav, S, Ikoma, N, Pestana, R, Vauthey, J, Cao, H, Chun, Y, Sakamura, D, Wolff, R, Yao, J, Allison, J & Sharma, P 2019, 'Randomized, open-label, perioperative phase II study evaluating nivolumab alone versus nivolumab plus ipilimumab in patients with resectable HCC', Annals of Oncology, vol. 30, pp. iv112. https://doi.org/10.1093/annonc/mdz156.008

@article{73265b770cee4919b1c5c415a5be801a,

title = "Randomized, open-label, perioperative phase II study evaluating nivolumab alone versus nivolumab plus ipilimumab in patients with resectable HCC",

author = "A. Kaseb and L. Vence and J. Blando and S. Yadav and N. Ikoma and R. Pestana and J. Vauthey and H. Cao and Y. Chun and D. Sakamura and R. Wolff and J. Yao and J. Allison and P. Sharma",

year = "2019",

month = jul,

doi = "10.1093/annonc/mdz156.008",

language = "English (US)",

volume = "30",

pages = "iv112",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

}

TY - JOUR

T1 - Randomized, open-label, perioperative phase II study evaluating nivolumab alone versus nivolumab plus ipilimumab in patients with resectable HCC

AU - Kaseb, A.

AU - Vence, L.

AU - Blando, J.

AU - Yadav, S.

AU - Ikoma, N.

AU - Pestana, R.

AU - Vauthey, J.

AU - Cao, H.

AU - Chun, Y.

AU - Sakamura, D.

AU - Wolff, R.

AU - Yao, J.

AU - Allison, J.

AU - Sharma, P.

PY - 2019/7

Y1 - 2019/7

UR - http://www.scopus.com/inward/record.url?scp=85079810166&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85079810166&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdz156.008

DO - 10.1093/annonc/mdz156.008

M3 - Article

C2 - 32084976

SN - 0923-7534

VL - 30

SP - iv112

JO - Annals of Oncology

JF - Annals of Oncology

ER -

Randomized, open-label, perioperative phase II study evaluating nivolumab alone versus nivolumab plus ipilimumab in patients with resectable HCC

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this